| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d7659d4abda44bced13b5edc01e96aab |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 |
| filingDate |
2019-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c44da23101d00f62d3895b6e12b4255
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbfd2887fad0014713367f6706240da7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03ee4f6579c58586416734fedffc8998 |
| publicationDate |
2021-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11066671-B2 |
| titleOfInvention |
Use of therapeutic agents |
| abstract |
The specification relates to the use of Mcl-1 inhibitors to promote apoptosis in vascular endothelial cells undergoing neovascularisation in disease states. |
| priorityDate |
2014-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |